Combination of ruthenium(II)-arene complex [Ru(η(6)-p-cymene)Cl(2)(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated as alternatives to other well-established metal-based chemotherapeutics. The organometallic compound [Ru(η(6)-p-cymene)Cl(2)(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) exhibits broad ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Berndsen, Robert H., Weiss, Andrea, Abdul, U. Kulsoom, Wong, Tse J., Meraldi, Patrick, Griffioen, Arjan W., Dyson, Paul J., Nowak-Sliwinska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320450/
https://www.ncbi.nlm.nih.gov/pubmed/28223694
http://dx.doi.org/10.1038/srep43005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320450/
https://www.ncbi.nlm.nih.gov/pubmed/28223694
http://dx.doi.org/10.1038/srep43005

Ejemplares similares